Truist Securities Initiates Coverage On Minimed Group with Buy Rating, Announces Price Target of $29

Truist Securities analyst Richard Newitter initiates coverage on Minimed Group (NASDAQ:MMED) with a Buy rating and announces Price Target of $29.